Summit Therapeutics Inc (SMMT) FinancialsSMMTSummit Therapeutics Inc

Evaluating the bottom line, Summit Therapeutics Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -192.50%, provide a clear picture of how effectively SMMT converts its operational activities into shareholder value.

In the context of the broader market, SMMT competes directly with industry leaders such as ELAN and TECH. With a market capitalization of $12.42B, it holds a leading position in the sector. When comparing efficiency, SMMT's gross margin of N/A stands against ELAN's 48.17% and TECH's 66.02%. Such benchmarking helps identify whether Summit Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

Summit Therapeutics has reported significant net income losses, with a net income of -565.7 million USD in Q2 2025 and -215.7 million USD in Q2 2026. The forward P/E ratio is 3.7216, indicating potential undervaluation, but the company has a negative price-to-sales ratio and a high price-to-book ratio of 19.46, reflecting financial instability.